All > Albuquerque > Mri

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging for Glioblastoma (GBM)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Glioblastoma (GBM)+1 MoreDynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial uses DSC-MRI to measure rCBV to determine response to bevacizumab in patients with recurrent glioblastoma. DSC-MRI may help to evaluate changes in cancer blood vessels.

Eligible Conditions
  • Glioblastoma (GBM)
  • Gliosarcoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Quality-of-Life Assessment
1
Pembrolizumab
1
Dynamic susceptibility contrast (DSC) MRI

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Up to 5 years

Baseline
CBF
rCBV
Baseline to 2 weeks
Change in CBF
Change in rCBV within enhancing tumor
Up to 5 years
OS
PFS

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Quality-of-Life Assessment
1
Pembrolizumab
2
Dynamic susceptibility contrast (DSC) MRI

Trial Design

1 Treatment Group

Diagnostic (DSC-MRI)
1 of 1

Experimental Treatment

146 Total Participants · 1 Treatment Group

Primary Treatment: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · No Placebo Group · N/A

Diagnostic (DSC-MRI)
DiagnosticTest
Experimental Group · 1 Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · Intervention Types: DiagnosticTest
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
2006
Completed Early Phase 1
~290

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

ECOG-ACRIN Cancer Research GroupLead Sponsor
103 Previous Clinical Trials
171,889 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,071 Previous Clinical Trials
41,128,709 Total Patients Enrolled
Jerrold BoxermanPrincipal InvestigatorECOG-ACRIN Cancer Research Group

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The presence of a tumor in the setting of progressive enhancement on MRI is strongly associated with the development of tumor recurrence.
Patients who have a new recurrence of their disease within 3 months of treatment with bevacizumab, and have no contraindications to bevacizumab, are eligible for this trial.
You have not been treated previously with immunotherapies (vaccines, checkpoint inhibitors, T-cells).
Patients must be able to tolerate brain MRI scans with dynamic intravenous gadolinium-based contrast agent injections.
You have a histologically proven intracranial glioblastoma or gliosarcoma at initial surgery.
You have a Karnofsky performance status of 70 or higher.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top